此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Gene Expression and FDG PET/MRI in Evaluating Treatment Response in Patients With Locally Advanced Rectal Cancer Undergoing Chemotherapy and Radiation Therapy Before Surgery

2016年12月7日 更新者:Washington University School of Medicine

Pilot Study of Gene Expression and FDG-PET/MR Biomarkers for Evaluation of Response to Neoadjuvant Therapy for Locally Advanced Rectal Cancer

This pilot clinical trial studies gene expression analysis and fludeoxyglucose F 18 (FDG) positron emission tomography (PET)/magnetic resonance imaging (MRI) in evaluating treatment response in patients with rectal cancer that has spread to nearby tissue or lymph nodes undergoing chemotherapy and radiation therapy before surgery. Studying samples of tissue in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and may also help doctors predict a patient's response to treatment before surgery. PET-MRI is a procedure that combines the pictures from a PET scan and an MRI scan. The combined scans give more detailed pictures of areas inside the body than either scan gives by itself. PET-MRI may help determine how well people respond to pre-surgery chemotherapy and radiation therapy and help the surgeon make the best plan for removal of the tumor.

研究概览

研究类型

介入性

注册 (实际的)

2

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Missouri
      • St. Louis、Missouri、美国、63110
        • Washington University School of Medicine

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Biopsy-proven adenocarcinoma of the rectum.
  • Surgical candidate.
  • Candidate for neoadjuvant chemotherapy.
  • Clinical evidence of T1-3N1 or T3N0 disease. This can be either by imaging studies or by physical exam findings.
  • At least 18 years of age.
  • Zubrod performance status of 0-2.
  • Able to understand and willing to sign a written informed consent document.
  • Patients with distant metastatic disease will be eligible if they satisfy all other conditions.

Exclusion Criteria:

  • Pregnant.
  • Past history of pelvic radiotherapy.
  • Received prior chemotherapy for colorectal cancer.
  • Uncontrolled diabetes with a fasting glucose ≥ 200 mg/dl at the time of PET/MRI imaging.
  • Claustrophobia or any other contraindication to MRI imaging evaluated by a standardized safety questionnaire.
  • Renal insufficiency (defined as glomerular filtration rate (GFR < 30 mL/min/1.73 m2) measured no more than 60 days before the first research scan) which precludes safe administration of the contrast agent.
  • Currently on dialysis.
  • Known prior allergic reaction to gadolinium-based MR contrast agents.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:诊断
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Diagnostic (FDG PET/MRI, gene expression)
FDG PET/MRI at baseline and at 2-4 weeks before surgery (after neoadjuvant chemoradiation). Tissue samples for gene expression at baseline and during surgery
相关研究
Undergo FDG PET/MRI
其他名称:
  • 18 FDG, 18FDG, 2-F18-fluoro-2-deoxy-D-glucose, 2-F18-fluoro-2-deoxyglucose, 63503-12-8, FDG, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18
Undergo FDG PET/MRI
其他名称:
  • FDG-PET、PET、PET 扫描、断层扫描、发射计算
Undergo FDG PET/MRI
其他名称:
  • MRI, NMR imaging, NMRI, nuclear magnetic resonance imaging

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in FDG-PET/MR SUVmax
大体时间:Baseline to up to 2 weeks before surgery
Images will be evaluated semi-quantitatively. Changes in imaging parameters will be correlated with pathologic response.
Baseline to up to 2 weeks before surgery
Change in FDG-PET/MR SUVmean
大体时间:Baseline to up to 2 weeks before surgery
Images will be evaluated semi-quantitatively. Changes in imaging parameters will be correlated with pathologic response.
Baseline to up to 2 weeks before surgery
Change in ADCmean
大体时间:Baseline to up to 2 weeks before surgery
Images will be evaluated semi-quantitatively. Changes in imaging parameters will be correlated with pathologic response.
Baseline to up to 2 weeks before surgery
Radiosensitivity index
大体时间:Baseline
Index is calculated based on tumor gene expression. Will be correlated with the descriptive changes in FDG-PET/MR SUV and ADC parameters.
Baseline

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2014年6月1日

初级完成 (实际的)

2015年3月1日

研究完成 (实际的)

2016年12月1日

研究注册日期

首次提交

2014年4月9日

首先提交符合 QC 标准的

2014年4月10日

首次发布 (估计)

2014年4月11日

研究记录更新

最后更新发布 (估计)

2016年12月8日

上次提交的符合 QC 标准的更新

2016年12月7日

最后验证

2016年12月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅